Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06745323 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
A Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Amgen.
- Active
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT06745323: Active Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Amgen.
NCT06745323 is a Phase 2 study of Small Cell Lung Cancer (SCLC) that is active but no longer recruiting, run by Amgen. The registered enrollment target is 252 participants, roughly in line with the 273-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06745323, a Phase 2 study of Small Cell Lung Cancer (SCLC), is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
Conditions Studied
Interventions
- DRUG Tarlatamab
Study Locations (20)
Other
- Grand Hopital de Charleroi - Site des Viviers - Charleroi
- Universitair Ziekenhuis Antwerpen - Edegem
- Jessa Ziekenhuis - Campus Virga Jesse - Hasselt
North Carolina
- Duke University - Durham
- FirstHealth Cancer Center - Pinehurst
Tennessee
- Tennessee Oncology PLLC - Chattanooga - Chattanooga
- Tennessee Oncology, PLLC - Nashville
Buenos Aires
- Fundacion Respirar - Ciudad Autonoma de Buenos Aires
- Instituto de Investigaciones clinicas de Mar del Plata - Mar del Plata
Victoria
- Monash Medical Centre - Clayton
- Austin Health, Austin Hospital - Heidelberg
California
- University of California Los Angeles - Los Angeles
Connecticut
- Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut - Plainville
Florida
- AdventHealth Hematology and Oncology - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2029-02-09 |
| Phase | Phase 2 |
What the registry record for NCT06745323 still lists
NCT06745323 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 273-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target.
The record links to 1 condition, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 1 intervention - of which Tarlatamab is the first listed.
NCT06745323 names 20 study sites across 14 states, led by Other, North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06745323 about?
NCT06745323 is a clinical study titled "A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC". The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
What is the current status of trial NCT06745323?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2025-02-26. Estimated completion is 2029-02-09.
What conditions does trial NCT06745323 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC).
What interventions are being tested in trial NCT06745323?
The interventions under investigation include: Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT06745323?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06745323 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06745323's enrollment target sits among peer trials
252 5th of 12 higher than 8 of 12 other Small Cell Lung Cancer (SCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Cancer (SCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RECRUITING · Phase 2
-
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
RECRUITING · Phase 2
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI